Brief · 2026-09-29

Brain tumors dominate today's brief: TVAX's phase 2/3 adoptive T cell trial in MGMT-unmethylated GBM and a phase 1 neoantigen-loaded DC vaccine at Beijing Tiantan both push personalized immunotherapy into one of the field's hardest indications.trial trial

On the enabling side, a Cancer Discovery study shows blood can largely stand in for tumor tissue in neoantigen discovery, while a preprint benchmark cautions that MHC-II prediction tools perform inconsistently across scenarios.news bioRxiv A vendor-published market forecast rounds out the day — directionally interesting, methodologically unverified.openPR.com

ClinicaltodayNew

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

TVAX Biomedical's randomized phase 2/3 study of TVI-Brain-1 plus standard therapy versus standard therapy alone in newly diagnosed MGMT-unmethylated GBM is now active, not recruiting — enrolled and in follow-up. The design is a closed autologous loop: a vaccine built from the patient's resected tumor expands neoantigen-specific effector T cell precursors, which are harvested from blood, stimulated and expanded ex vivo, then reinfused. Reaching phase 2/3 in GBM places this among the more advanced neoantigen-directed adoptive T cell programs, with randomized, standard-of-care-controlled data as the bar.

clinicaltrials · today · TVAX Biomedical

Also new today05

CommercialtodayNew

Personalized Cancer Vaccines Market to Reach US$ 30.12 Billion - openPR.com

A DataM Intelligence press release forecasts the personalized cancer vaccines market reaching US$30.12 billion by 2033 at an 11.5% CAGR, naming Gritstone Bio, CureVac, and Transgene as key players. Treat the figures as directional: this is vendor-published via openPR, not peer-reviewed, with no methodology disclosed. The signal worth noting is continued third-party framing of personalized immunotherapy as a growth market through the next decade.

news · today · openPR.com

AI / MethodstodayNew

Blood tests can identify cancer neoantigens for personalized immunotherapy - News-Medical

A Cancer Discovery study from the Vall d'Hebron Institute of Oncology (senior author Alena Gros, first author Andrea Garcia-Garijo) identified neoantigens from circulating tumor DNA and neoantigen-specific T cells from blood immune cells — and these largely matched what traditional tumor tissue biopsy showed in many patients. If blood holds up as a tissue substitute, vaccine target selection and immune monitoring become feasible without surgery or fresh biopsy, and serial sampling over a treatment course becomes practical. That is a meaningful operational unlock for personalized vaccine and T cell therapy pipelines.

news · today · News-Medical

ClinicalyesterdayNew

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

Beijing Tiantan Hospital is running a single-center, open-label phase 1 of ZSNeo-DC1.1, an autologous, genetically unmodified dendritic cell vaccine loaded with multiple tumor neoantigen peptides, in roughly 15 adults with recurrent or progressive WHO grade III-IV glioma after reoperation. The protocol uses a fixed 1×10^7-cell dose, two immunization schedules, and a DLT window running to 21 days after the third injection, starting with a six-subject dose confirmation stage. It adds a China-based safety and preliminary efficacy datapoint for personalized DC vaccines in recurrent high-grade glioma post-standard treatment.

clinicaltrials · yesterday · Beijing Tiantan Hospital

AI / MethodsyesterdayNew

PREpiBind: Protein Representation-integrated Epitope--MHC Class II Binding Prediction

PREpiBind benchmarks ten protein representations inside a single joint-attention architecture for peptide-MHC class II binding prediction under fixed data splits; ESM3 Large reached ROC-AUC 0.927±0.002 on the qualitative dataset. PLM-based variants exceeded reference methods on qualitative and mass spectrometry benchmarks, but NetMHCIIpan-4.3 retained the edge on thresholded IC50 via its affinity head, and PLM advantages narrowed in allele-wise and held-out-MHC evaluations. The takeaway for vaccine target selection: no single representation wins everywhere — benchmark against your specific allele and data-type regime.

biorxiv · yesterday · Jang, D. H.; Hwang, U.; Kim, D.; Park, B.; Choi, Y.; Lee, J.

AI / MethodsyesterdayNew

Integrated immunopeptidomics and transcriptomics reveal a cancer-restricted non-canonical HLA class I ligandome in medulloblastoma

A preprint integrating immunopeptidomics and transcriptomics across all four medulloblastoma subgroups (Group 3, Group 4, WNT, SHH) mapped the non-canonical HLA class I ligandome: 2,298 non-canonical peptides across 21 samples, of which 598 were cancer-restricted after filtering against normal-tissue immunopeptidomic and ribosome profiling data. These derive from retained introns, out-of-frame open reading frames, and lncRNAs rather than mutations — significant because medulloblastoma's low mutational burden limits mutation-derived neoantigens. Some cancer-restricted candidates are shared across patients, pointing to targets usable beyond single-patient personalization.

biorxiv · yesterday · Hui, A.; Zheng, N.; Xu, Y.; Mai, W.

Neoantigen T cell and DC vaccine trials target glioblastoma